OKYO PHARMA LTD Aktie

Raj Patil, chief scientific officer of OKYO Pharma, bought 3,363 common shares on the NASDAQ at $1.49 each, bringing his holdings to 20,030 shares. OKYO Pharma is preparing to start a global phase‑3 trial in the second half of the year with about 111 patients to evaluate a single dose of urcosimod for neuropathic corneal pain. » Więcej na de.investing.com

Chief Executive Officer Robert J. Dempsey purchased 15,000 common shares of OKYO Pharma on the open market at $1.54 per share on the NASDAQ. OKYO Pharma is listed on the Nasdaq Capital Market and plans to start a global phase‑3 single‑dose study of urcosimod for neuropathic corneal pain in the second half of the year with about 111 patients. The company is in the clinical development phase for anterior segment eye therapies. » Więcej na de.investing.com

Gary S. Jacob, chief development officer and director of OKYO Pharma, purchased 3,500 common shares at $1.40 each on the Nasdaq, bringing his total holding to 112,420 shares. OKYO Pharma’s common stock is listed on the Nasdaq Capital Market. The biopharmaceutical company plans to start a global, registration‑enabling Phase 3 study of urcosimod for the treatment of neuropathic corneal pain in the second half of the year, likely with around 111 patients and a single‑dose regimen. » Więcej na de.investing.com